drugset / Trial / NCT00080990

Alvocidib, Oxaliplatin, Fluorouracil, and Leucovorin Calcium in Treating Patients With Advanced Solid Tumors

NCT00080990

Phase 1 Completed 46 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase I trial is studying the side effects and best dose of alvocidib when given together with oxaliplatin, fluorouracil, and leucovorin calcium in treating patients with advanced solid tumors. Drugs used in chemotherapy, such as alvocidib, oxaliplatin, fluorouracil, and leucovorin calcium, work in different ways to stop tumor cells from dividing so they stop growing or die. Alvocidib may also make tumor cells more sensitive to chemotherapy. Combining more than one chemotherapy drug may kill more tumor cells.

Timeline

Start
2004-02
Primary completion
2009-04
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject alvocidib Small molecule Intravenous
Background Leucovorin Small molecule Intravenous
Background Oxaliplatin Small molecule Intravenous
Background fluorouracil Small molecule Intravenous

Indications

No indication recorded.